methyl 4-piperidin-4-yl>but-2-enoate | 142355-80-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: methyl 4-piperidin-4-yl>but-2-enoate
• 英文别名: Tert-butyl 4-(4-methoxy-4-oxobut-2-enyl)piperidine-1-carboxylate
• CAS: 142355-80-4
• 化学式: C₁₅H₂₅NO₄
• 分子量: 283.368
• InChiKey: MTQBOSAYKRQDRQ-UHFFFAOYSA-N

物化性质

• 沸点：
  364.1±15.0 °C(Predicted)
• 密度：
  1.053±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  methyl 4-piperidin-4-yl>but-2-enoate 在 palladium on activated charcoal sodium hydroxide 、 四溴化碳 、 硼烷 、 氢气 、 sodium hydride 、 caesium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 74.0h， 生成 替罗非班中间体
  参考文献：
  名称：

  Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp

  摘要：

  Inhibitors of platelet-fibrinogen binding offer an opportunity to interrupt the final, common pathway for platelet aggregation. Small molecule inhibitors of the platelet fibrinogen receptor GPIIb/IIIa were prepared and evaluated for their ability to prevent platelet aggregation. Compound 23m (L-700,462/MK-383) inhibited in vitro platelet aggregation with an IC50 of 9 nM and demonstrated a selectivity of > 24 000-fold between platelet and human umbilical vein endothelial cell fibrinogen receptors. Dose-dependent inhibition of ex vivo platelet aggregation induced by ADP was achieved with iv infusions of 0.1-10 mu g/kg/min of 23m in anesthetized dogs, with 10 mu g/kg/min completely inhibiting platelet aggregation during the entire 6 h infusion protocol. Platelet aggregatability returned rapidly after the termination of the 23m infusions. These features suggest that 23m may be useful in the treatment of arterial occlusive disorders.

  DOI：

  10.1021/jm00042a007
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 草酰氯 、 二甲基亚砜 、 三乙胺 、 lithium chloride 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 23.25h， 生成 methyl 4-piperidin-4-yl>but-2-enoate
  参考文献：
  名称：

  HETEROCYCLIC COMPOUNDS AS STING AGONISTS

  摘要：

  The disclosure relates to a compound represented by Formula 1, or a pharmaceutically acceptable salt thereof, as a stimulator of interferon genes (STING) agonist, pharmaceutical compositions comprising the same, and related methods of and uses in treatment or prevention of disease.

  公开号：

  WO2024100452A2

文献信息

• [EN] PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS<br/>[FR] COMPOSES DE PIPERIDINYLE LIANT SELECTIVEMENT LES INTEGRINES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004020435A1

  公开（公告）日：2004-03-11

  The invention is directed to piperidinyl compounds of formula (I) and (II) that selectively bind integrin receptors and methods for treating an integrin mediated disorder, wherein W, R2, Z and q are described in the application.

  这项发明涉及选择性结合整合素受体的式(I)和(II)的哌啶基化合物，以及治疗整合素介导的疾病的方法，其中W、R2、Z和q在申请中有描述。
• Synthesis of β-Silyl-α-amino Acid Derivatives by Cu-Catalyzed Regio- and Enantioselective Silylamination of α,β-Unsaturated Esters
  作者：Toshimichi Kobayashi、Soshi Nishino、Masahiro Miura、Koji Hirano

  DOI：10.1021/acs.orglett.2c00309

  日期：2022.2.18

  silylamination of α,β-unsaturated esters with silylboranes and hydroxylamines has been developed to afford the corresponding β-silyl-α-amino acid derivatives, which are of great interest in medicinal and pharmaceutical chemistry. Additionally, by using a suitable chiral bisphosphine ligand, the asymmetric induction is possible, delivering the optically active β-silyl-α-amino acids with synthetically

  已开发出铜催化的 α,β-不饱和酯与甲硅烷基硼烷和羟胺的甲硅烷基化反应，得到相应的 β-甲硅烷基-α-氨基酸衍生物，这在药物和药物化学中具有重要意义。此外，通过使用合适的手性双膦配体，不对称诱导是可能的，以合成可接受的非对映体比 (55:45–82:18 dr) 和高对映体比 (81: 19–99:1 呃）。
• [EN] ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES<br/>[FR] PEPTIDES ET PSEUDOPEPTIDES A GROUPE AZACYCLOALKYLALCANOYLE AYANT DES PROPRIETES ANTITHROMBOTIQUES
  申请人：RHONE-POULENC RORER PHARMACEUTICALS INC.

  公开号：WO1995010295A1

  公开（公告）日：1995-04-20

  (EN) The present invention relates to azacycloalkylalkanoyl peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease, and disseminated intravascular coagulation, to methods for the prevention or treatment of thrombosis in a mammal in need of such therapy comprising the administration of a therapeutically effective amount of such compounds, and to pharmaceutical compositions comprising such compounds.(FR) La présente invention concerne des peptides ou pseudopeptides à groupe azacycloalkylalcanoyle qui inhibent l'agrégation plaquettaire et la formation de thrombus, ce qui les rend utiles dans la prévention et le traitement de thromboses que l'on rencontre dans des états pathologiques tels que l'infarctus du myocarde, les accidents cérébrovasculaires, les maladies vasculaires périphériques, et la coagulation intravasculaire disséminée. L'invention concerne également des méthodes de prévention ou de traitement de thromboses chez des mammifères nécessitant une telle thérapie, consistant à d'administrer une dose appropriée de tels composés, ainsi que des compositions pharmaceutiques comprenant de tels composés.

  本发明涉及抑制血小板聚集和血栓形成的氮杂环烷基烷酰肽和假肽，因此可用于预防和治疗与疾病状态相关的血栓形成，如心肌梗死、中风、外周动脉疾病和弥漫性血管内凝血，以及用于治疗需要此类治疗的哺乳动物的预防或治疗血栓形成的方法，包括给予这些化合物的治疗有效量，以及包含这些化合物的制药组合物。
• Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
  申请人：——

  公开号：US20020002268A1

  公开（公告）日：2002-01-03

  The present invention relates to azacycloalkylalkanoyl peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease, and disseminated intravascular coagulation, to methods for the prevention or treatment of thrombosis in a mammal in need of such therapy comprising the administration of a therapeutically effective amount of such compounds, and to pharmaceutical compositions comprising such compounds.

  本发明涉及抑制血小板聚集和血栓形成的氮杂环烷基烷酰肽和伪肽，因此在预防和治疗与疾病状态相关的血栓形成，如心肌梗死、中风、外周动脉疾病和弥漫性血管内凝血等方面具有用处，以及用于预防或治疗哺乳动物中需要此类治疗的方法，包括给予这些化合物的治疗有效量，以及包含这些化合物的制药组合物。
• Piperidinyl compounds that selectively bind integrins
  申请人：De Corte Bart

  公开号：US20080058359A1

  公开（公告）日：2008-03-06

  The invention is directed to piperidinyl compounds that selectively bind integrin receptors and methods for treating an integrin mediated disorder.

  这项发明涉及选择性结合整合素受体的哌啶化合物以及治疗整合素介导疾病的方法。